A new experimental drug was found to "significantly" reduce the progression of brain cancer, Reuters reported.
Vorasidenib, created by Servier Group, a private drug developer, was shown to slow the progression of brain tumors by an average of over 16 months, per Bloomberg. The results of the 331-patient study were published June 4 in The New England Journal of Medicine.
The study's lead author, Ingo Mellinghoff, described this as "a very big finding," adding that the drug "is the first molecularly targeted treatment for diffuse glioma." Vorasidenib specifically works on Grade 2 gliomas, which are "progressive, malignant brain tumors" that are "more common in adults but can also occur in children and teenagers," according to Reuters. The drug blocks a specific enzyme mutated in low-grade gliomas, keeping them from progressing and postponing the need for further treatment like chemotherapy.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"What you just heard is a trial that was well done and well thought out: to use an oral, targeted, well-tolerated therapy to see if we could delay the use of our standard chemotherapy and radiation," Wake Forest Baptist Health's Dr. Glenn Lesser commented at an American Society of Clinical Oncology briefing. "The results are quite striking and they're statistically highly significant, and more importantly, they're clinically very, very significant."
Servier Group is working to get the drug approved by the Food & Drug Administration for use in the U.S.
-
‘The Taliban delivers yet another brutal blow’Instant Opinion Opinion, comment and editorials of the day
-
Renewables top coal as Trump seeks reversalSpeed Read For the first time, renewable energy sources generated more power than coal, said a new report
-
Prime minister shocks France with resignationSpeed Read French Prime Minister Sebastien Lecornu submitted his government’s resignation after less than a month in office
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
‘Nightmare bacteria’ are rapidly spreadingUnder the radar The infections are largely resistant to antibiotics
-
Kissing bug disease has a growing presence in the USThe explainer The disease has yielded a steady stream of cases in the last 10 years
-
Climate change is making us eat more sugarUnder the radar Sweets make the heat feel more manageable
-
Trump makes unmoored claims on Tylenol and autismSpeed Read No causal relationship has been established between autism and acetaminophen use during pregnancy
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Human evolution may be responsible for autism ratesUnder the radar Neurodiversity and a complex brain may go hand in hand
